Age-related macular degeneration (AMD) causes blindness due to loss of retinal pigment epithelium (RPE) and photoreceptors (PRs), which comprise the two outermost layers of the retina.
David Gamm
Research beyond Waisman Center: Discoveries that have spun into products
Multiple discoveries born from the minds and hard work of Waisman Center investigators have left the nest to become successful companies or products that have had a significant impact in the world through translational research.
UW researchers will trial gene editing therapy to treat blindness
Hope for Failing Eyes
Retinal cells grown from stem cells can reach out and connect with neighbors, according to a new UW study, completing a “handshake” that may show the cells are ready for trials in humans with degenerative eye disorders.
David Gamm works to bring research and medicine into a single vision
David Gamm is adept at keeping multiple things in focus. Gamm, MD, PhD, is a Waisman investigator, director of the McPherson Eye Research Institute, and professor of ophthalmology and visual sciences. With one eye trained on patients, he treats children in the pediatric ophthalmology clinic.
Lab-grown retinal eye cells make successful connections, open door for clinical trials to treat blindness
Retinal cells grown from stem cells can reach out and connect with neighbors, according to a new study, completing a “handshake” that may show the cells are ready for trials in humans with degenerative eye disorders.
David Gamm, MD, PhD – Slide of the Week
Interphotoreceptor matrix proteoglycan 2 (IMPG2) mutations cause a severe form of early-onset retinitis pigmentosa (RP) with macular involvement.
New funding moves David Gamm’s retinitis pigmentosa treatment research into phase two
A grant from Fighting Blindness Canada will allow Dave Gamm to further test the efficacy of an induced pluripotent stem cell (iPSC) derived treatment that aims to replace damaged photoreceptor cells and restore some measure of vision.
David Gamm, MD, PhD – Slide of the Week
Polymeric scaffolds are revolutionizing therapeutics for blinding disorders affecting the outer retina, a region anatomically and functionally defined by light-sensitive photoreceptors. Recent engineering advances have produced planar scaffolds optimized for retinal pigment epithelium monolayer delivery, which are being tested in early stage clinical trials.
UW vision researchers partner with U.S. Department of Defense to develop stem cell therapy for combat-related eye injuries
The new project, titled Outer Retina Reconstruction for Combat Afflictions or ORRCA, is a collaboration between the McPherson Eye Research Insitute at UW‒Madison, the UW School of Medicine and Public Health, the UW College of Engineering, the University of Birmingham (UK) and British Ministry of Defence and the National Eye Institute. It is funded by a grant for more than $5 million from the U.S. Department of Defense (DOD).